Roger Jones, MD
General Practice · Clinton, INNPI 1457347379
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $75,875 of the $78,013 with a category attached, or 97.3%. CSL Plasma Inc. accounts for 97.3% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $26,000, more than ten times the $687 reported in 2019. Among general practice clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $481.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$76K
- Lilly USA, LLC$427
- AbbVie$349
- GSK$200
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$144
- Radius Health, Inc.$125
- plus $894 from 17 others
What the payments were for
- Consulting fees$75,87597%
- Food & beverage$2,1383%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 76 | $75,875 |
| Lilly USA, LLC | 13 | $427 |
| AbbVie(2 entities) | 20 | $349 |
| GSK | 7 | $200 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $144 |
| Radius Health, Inc. | 1 | $125 |
| Novartis | 2 | $121 |
| Novo Nordisk | 3 | $114 |
| Lundbeck LLC | 6 | $107 |
| Endo Pharmaceuticals Inc. | 5 | $97 |
| Amgen | 5 | $95 |
| Mylan Specialty L.p. | 1 | $89 |
| Indivior Inc. | 2 | $54 |
| Pfizer | 3 | $53 |
| Bayer | 2 | $32 |
| Shield Therapeutics Inc | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| Abbott | 1 | $18 |
| Merck | 1 | $17 |
| Masimo Corporation | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Orexo US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$227
- TRELEGY ELLIPTA$125
- Tymlos$125
- ENTRESTO$100
How this compares
$78,013 in reported general payments places this provider in the 95th percentile of 1,558 general practice providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 83 | $91,745 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $52,729 |
| TrulicityDulaglutide | 23 | $32,721 |
| JardianceEmpagliflozin | 22 | $29,957 |
| OzempicSemaglutide | 13 | $25,936 |
| FarxigaDapagliflozin Propanediol | 13 | $21,980 |
| CreonLipase/Protease/Amylase | 14 | $21,540 |
| EntrestoSacubitril/Valsartan | 13 | $18,046 |
| Repatha SureclickEvolocumab | 13 | $16,779 |
| EliquisApixaban | 13 | $14,853 |
| Nurtec OdtRimegepant Sulfate | 12 | $11,700 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,401 |
| Ezetimibe | 47 | $2,845 |
| Aripiprazole | 19 | $2,207 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $427 | $124,466106 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $200 | $57,12952 claims |
| PfizerEliquis, Nurtec Odt | $53 | $26,55325 claims |
| Novo NordiskOzempic | $114 | $25,93613 claims |
| AstraZenecaFarxiga | $13 | $21,98013 claims |
| AbbVieCreon | $349 | $21,54014 claims |
| NovartisEntresto | $121 | $18,04613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,558 general practice providers in Indiana.
Other general practice in Clinton
- Tina GermanWarsaw$260K
- Kenneth TroutmanHuntingburg$124K
- Daniel KlauerGranger$45K
- William FloraElkhart$39K
- Ryan HolmesFort Wayne$33K
- Samuel CoreyFort Wayne$27K
- Kara WulffMuncie$23K
- Gary WalkerFishers$19K
- Adam HubertEvansville$15K
- Christopher GreenLebanon$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.